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Summary
Objectives: We evaluated the prevalence of primary HIV drug resistance in a population of 128
injection drug users (48 female) prior to initiating antiretroviral therapy.
Methods: Genotypic and phenotypic profiles were obtained retrospectively for the period June
1996 to February 2007. Genotypic drug resistance was defined as the presence of a major
mutation (IAS-USA table, 2007 revision), adding revertants at reverse transcriptase (RT) codon
215. Phenotypic drug resistance was defined as the fold change associated with 80% loss of the
wild type virologic response due to viral resistance based on virtual phenotype analysis.
Results: Genotypic drug resistance was uncommon, and was only identified in six (4.7%) cases, all
in the RT gene (L100I, K103N, Y181C, M184V, Y188L, and T215D). There were no cases of multi-
class or protease inhibitor (PI) resistance. However, polymorphisms in the protease and RT genes
were extremely common. Phenotypic drug resistance was also identified in six (4.7%) patients,
four in the RT gene (in patients with mutations K103N, Y181C, M184V and Y188L) and two the
protease gene (in two patients with minor PI mutations). In addition, 25 (19.5%) of the patients
had reduced susceptibility to PIs, defined as resistance >20% but <80% of the wild type virologic
response, with no primary PI mutations detected in all these patients.
Conclusion: The prevalence of primary HIV drug resistance was low in this population of injection
drug users.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Highly active antiretroviral therapy (HAART) for the treat-
ment of HIV infection has significantly improved survival
and reduced progression to AIDS.1 However, the develop-
ment of resistance to antiretroviral drugs is a major
obstacle that can limit the long-term efficacy of HAART.2
Resistance to antiretroviral drugs in previously untreated
patients, defined as primary HIV drug resistance, is of
growing importance. In recent seroconverters and treat-
ment-naı¨ve patients, its prevalence has increased to 5—
25% in certain population-based surveys.3—7 Among
untreated subjects of unknown duration of HIV infection,
the estimated prevalence of primary drug resistance is
similar.8—13 However, fewer studies have assessed the pre-
valence of primary drug resistance mutations in injection
drug users (IDUs). Data from one study demonstrated a
prevalence of 24% in this risk group.14
Novel strategies, such as directly observed therapy (DOT),
have been employed to administer HAART to IDUs.15—17 This
has been especially successful when combined with the
treatment of addiction. Co-administration of HAART with
methadone has led to levels of virologic suppression similar
to those reported in clinical trials. However, there is some
concern that even in the setting of DOT, this population is at
high risk for non-adherence and the development of second-
ary drug resistance. This, in turn, may lead to a dramatic rise
in the transmission of drug resistance to HIV-uninfected
individuals in the IDU community, as well as to individuals
who may come in contact with members of this community.
With this in mind, the current study was undertaken to
estimate the prevalence of mutations associated with drug
resistance in a cohort of antiretroviral-naı¨ve IDUs with estab-
lished chronic infection.
Methods
All HIV-infected IDUs attending an inner city community
health center in Vancouver, Canada from June 1996 to Feb-
ruary 2007 were identified and enrolled into this retrospec-
tive, observational study. The Pender Community Health
Centre is a multi-disciplinary healthcare facility providing
primary care, addiction services, and treatment of infectious
diseases predominantly to marginalized individuals in the
Downtown Eastside of Vancouver, an area with a high pre-
valence of illicit drug use. Individuals with newly diagnosed
HIV infection were eligible for baseline genotypic resistance
testing. Patients were excluded from the study if no blood
samples were available for resistance testing before the start
of any antiretroviral treatment.
Genotypic resistance testing was performed on archived
blood samples. The first available plasma samples were used
for resistance testing. Genotypic drug resistance testing was
done using the VirtualPhenotypeTM Assay (VIRCO Lab, Meche-
len, Belgium). Primary drug resistance was defined as the
presence of a major mutation according to the International
AIDS Society guidelines (IAS-USA table, 2007).18 Revertants at
reverse transcriptase (RT) codon 215 (A/C/D/E/G/H/I/L/N/
S/V) were also included. Secondary or minor mutations,
defined as mutations that have small impact on resistance,
were deemed polymorphisms, while isolates with no muta-
tions were classified as wild-type virus.Phenotypic drug resistance testing was assessed using
the virtual phenotype. The virtual phenotype is an estimate
of the phenotype (fold-changes in IC50) for a patient’s HIV
genotype by matching it with other genotypes available in
large databases in which they are paired with phenotypes.
Results of the analysis were expressed for each drug as
clinical cut-off values (CCO) with the lower (CCO1) and
upper (CCO2) clinical cut-offs being the baseline fold
change associated with 20% and 80% loss of the wild type
virologic response due to viral resistance, respectively.
Biological cut-off values (BCO), which indicate the normal
range of susceptibility of wild type HIV-strains to each drug
in vitro, were used where CCO values were not available.
Thus, to predict drug activity, HIV isolates were categorized
as sensitive, reduced susceptibility (CCO1), or resistant
(CCO2, BCO) for each drug based on cut-offs values
described by Virco.
Demographic data were collected at treatment baseline.
First-line antiretroviral regimens were chosen on an indivi-
dualized basis, but without taking into account the presence
of any pre-treatment drug resistancemutations, as genotypic
test results were only available retrospectively, long after
antiretroviral therapy was initiated. Since the date of HIV
infection was not available for the patients and since detuned
assays were not performed to determine whether the
patients had recent infection or not, all of the patients were
considered to have established chronic HIV infection. Anti-
retroviral agents were ingested under a community pharma-
cist’s supervision on a daily basis within a DOT program. HIV
plasma viral load was measured using the Amplicor HIV-1
MonitorTM assay, version 1.5 (Roche Diagnostics, Mississauga,
ON, Canada). Virologic suppression was defined as having a
plasma viral load <400 copies/ml at some point during
treatment, regardless of the follow-up period, as long as
the patient had a viral load measurement after initiating
first-line antiretroviral treatment. Immunologic response
was monitored using the CD4 cell count, measured by flow
cytometry at the local reference laboratory. HIV plasma viral
load and CD4 cell counts were measured at baseline, and at
approximately three-month intervals or more frequently if
clinically indicated.
Calculation of confidence intervals for the percentage of
patients with primary drug resistance was done using aWilson
score interval. In patients placed on first-line antiretroviral
therapy, the rates of virologic suppression following treat-
ment initiation were compared in patients with and without
primary resistance mutations. Tests for independence
between two discrete variables were done using the Chi-
square or Fisher’s exact test, as appropriate. All reported p-
values were two-sided, and p-values below a significance
level of 0.05 were considered statistically significant.
Results
Among the 174 IDUs screened, a total of 128 were included in
the analysis, of whom 48 (37.5%) were female. Forty-six
patients (18 female; mean age 45.6 years) were excluded
from the study because there were no stored blood samples
available for retrospective resistance testing. Most patients
were co-infected with hepatitis C virus (93.8% carrying anti-
HCVantibodies). The number of IDUs enrolled in the study per
year was as follows: 14 (1996), 11 (1997), 10 (1998), 17
Table 1 Baseline patient characteristics.
Number of patients 128
Sex
Female (%) 48 (37.5)
Male (%) 80 (62.5)
Age in years
Mean (SD) 42.8 (8.9)
Hepatitis C status
Positive (%) 120 (93.8)
Median plasma viral load (copies/ml) at HIV diagnosis
All patients (Q1—Q3) 71 150 (17 525—>100 000)
With primary resistance
(Q1—Q3)
64 250 (22 600—89 400)
Without primary resistance
(Q1—Q3)
71 150 (17 600—>100 000)
Median CD4 cell count (cells/mm3) at HIV diagnosis
All patients (Q1—Q3) 300 (180—480)
With primary resistance
(Q1—Q3)
425 (213—518)
Without primary resistance
(Q1—Q3)
300 (180—460)
Median plasma viral load (copies/ml) at treatment baseline
All patients (Q1—Q3) 90 300 (43 800—>100 000)
With primary resistance
(Q1—Q3)
56 300 (18 850—85 420)
Without primary resistance
(Q1—Q3)
95 300 (47 700—>100 000)
Median CD4 cell count (cells/mm3) at treatment baseline
All patients (Q1—Q3) 195 (117—358)
With primary resistance
(Q1—Q3)
220 (163—285)
Without primary resistance
(Q1—Q3)
195 (112—362)
Duration of HIV diagnosis (months)
Median (Q1—Q3) 2.9 (0.7—25.0)
Initiated antiretroviral therapy 101
NRTI-based 3
NNRTI-based 50
PI-based 48
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
Q1, first quartile; Q3, third quartile; SD, standard deviation.
Primary drug resistance in antiretroviral-naı¨ve injection drug users 579(1999), 12 (2000), 15 (2001), 4 (2002), 11 (2003), 9 (2004), 17
(2005), 4 (2006), and 4 (2007).
The mean age at the time of resistance testing was 42.8
years. At diagnosis, the median CD4 cell count was 300 cells/
mm3 and the median plasma viral load 71 150 copies/ml. The
median time from HIV diagnosis to drug resistance testing
was 86.5 days. All patients carried subtype B virus. Among
the 128 patients, 101 were then placed on first-line therapy,
with three receiving solely nucleoside reverse transcriptase
inhibitors (NRTIs), 50 non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based therapy, and 48 protease inhibitor
(PI)-based therapy. A clinical decision to delay HAART was
made in the other 27 cases. The baseline characteristics of
the patients are presented in Table 1.
Overall, six (4.7%, 95% confidence interval (CI) 2.2—9.8%)
had primary genotypic drug resistance, with the following
mutations in the RT gene: L100I (1), K103N (1), Y181C (1),
M184 V (1), Y188L (1), and T215D (1). By drug class, the
estimated prevalence of mutations conferring resistance was
1.6% (95% CI 0.4—5.5%) for NRTIs and 3.1% (95% CI 1.2—7.8%)
for NNRTIs (Table 2). There were no cases of multi-class
resistance or major PI resistance mutations. Moreover, there
was no significant temporal trend in the prevalence of muta-
tions by year of enrolment, with three of the identified cases
of primary resistance mutations occurring prior to the year
2000, and the remaining three occurring after the year 2000
(Table 3).
Among the non-major mutations, there were five patients
infectedwithsolitaryRTmutations includingT69S(3)andV118I
(2). Polymorphisms in the RT gene were common, occurring in
107 (83.6%) of the sequences. RT polymorphisms were present
at positions K20R (13), T39A (2), K43Q (1), A98S (7), K101Q (1),
K103R (2), V106I (3), V179I (9), V189I (1), H208Y (1), H221Q (1),
L283I (17), and G333E (9); however, the most common poly-
morphisms were associated with I135G/L/M/R/T/V (58) and
R211Q/K (66). Polymorphisms in the protease genewereextre-
mely common occurring in 115 (89.8%) of the sequences at the
following positions: L10I/V (15), I13 V (4), K20R (1), L33I (1),
E35D (59), M36I (38), K45R (2), Q58E (2), D60E (7), L63P (67),
A71T/V (24), V75I (1), V77I (37), and I93L (73).
Overall, six (4.7%, 95% CI 2.2—9.8%) patients had primary
phenotypic drug resistance for lamivudine/emtricitabine (1),
nevirapine/delavirdine/efavirenz (3), and nelfinavir (2)
(Tables 2 and 3). Four of the patients who had genotypic
resistance with K103N, Y181C, M184V, and Y188L mutations
had phenotypic resistance, while the two other patients with
mutations L100I and T215D had phenotypes within the normal
susceptible range (Table 3). On the other hand, two patients
with secondary PI mutations had primary phenotypic resis-
tance to nelfinavir (Table 3). By drug class, the estimated
prevalence of mutations conferring resistance was 0.8% (95%
CI 0.1—4.3%) for NRTIs, 2.3% (95% CI 0.8—6.7%) for NNRTIs,
and 1.6% (95% CI 0.4—5.5%) for PIs (Table 2). In addition, 25
(19.5%, 95% CI 13.6—27.2%) had reduced susceptibility to PIs
for the following antiretroviral drugs: 22 (17.2%, 95% CI 11.6—
24.7%) for nelfinavir, 16 (12.5%, 95% CI 7.8—19.3%) for indi-
navir, 13 (10.2%, 95% CI 6.0—16.6%) for amprenavir and two
(1.6%, 95% CI 0.4—5.5%) for saquinavir. Among the 25 patients
with reduced susceptibility to PIs, four had primary pheno-
typic resistance as well. However, in all patients with
reduced susceptibility to PIs, there were no primary PI
mutations detected.Following initiation of antiretroviral therapy, virologic
suppression, defined as reaching a detection limit of 400
copies/ml, was achieved at some point during treatment in
67/101 (66.3%) patients. Following the initiation of therapy,
suppression was first detected after a median of 90 days
Table 2 Prevalence of primary genotypic and phenotypic drug resistance.
Genotype Number (N = 128) Percentage 95% CI Mutations
All mutations 6 4.7 2.2—9.8 See below
NRTI mutations 2 1.6 0.4—5.5 M184V, T215D
NNRTI mutations 4 3.1 1.2—7.8 L100I, K103N, Y181C, Y188L
Phenotype Number (N = 128) Percentage 95% CI Resistance to antiretrovirals
All resistance 6 4.7 2.2—9.8 See below
NRTI resistance 1 0.8 0.1—4.3 Lamivudine/emtricitabine
NNRTI resistance 3 2.3 0.8—6.7 Nevirapine/delavirdine/
efavirenz
PI resistance 2 1.6 0.4—5.5 Nelfinavir
CI, confidence interval; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor.
580 H.K. Tossonian et al.(corresponding with the testing schedule for HIV plasma viral
load). All six patients who had primary genotypic drug resis-
tance initiated treatment; however, only three patients had
resistance mutations affecting first-line HAART (Table 3). In
patients with primary drug resistance, virologic suppression
was achieved in 4/6 (66.7%) cases with the two virologic
failures occurring in patients with relevant NNRTI mutations
(L100I, K103N). In patients without primary resistance, vir-
ologic suppression was achieved in 63/95 (66.3%, p = 0.99)
cases.
As shown in Table 3, all six patients who had primary
phenotypic drug resistance initiated treatment; however,
only one patient had phenotypic resistance affecting the
first-line HAART selected for them. In patients with primary
phenotypic resistance, virologic suppression was achieved in
5/6 (83.3%) cases, with one virologic failure occurring in the
patient with relevant NNRTI phenotypic resistance. In
patients without primary phenotypic resistance, virologic
suppression was achieved in 62/95 (65.3%, p = 0.66) cases.
Finally, among the 25 patients having reduced susceptibility
to PIs, 20 initiated antiretroviral therapy (one based on
NRTIs, seven on NNRTIs, and 12 on PIs) with similar rates
of virologic suppression achieved in patients with andwithout
reduced phenotypic susceptibility to PIs.
Discussion
In this study, the prevalence of primary genotypic drug
resistance was 4.7% in chronically infected treatment-naı¨ve
IDUs. Mutations conferring resistance to NNRTIs (3.1%) and
NRTIs (1.6%) were seen; however, there were no cases of
major PI resistance mutations or multi-class resistance.
Similarly, the prevalence of phenotypic drug resistance
was 4.7%, although the resistance profile using the virtual
phenotype analysis included resistance to NRTIs (0.8%),
NNRTIs (2.3%), and PIs (1.6%). In addition, 25 (19.5%) patients
had reduced susceptibility to PIs.
On the other hand, very high frequencies of polymorph-
isms in the RT (83.6%) and the protease genes (89.9%) were
detected. Although these have only a small impact on resis-
tance, theymay play a role in the viral fitness or the evolution
of resistance once drug pressure is applied. Alternatively,
they may simply be ‘signature’ mutations for the strains
being transmitted within this IDU community, as certainspecific patterns (such as genetic changes at codon 135 in
the RT gene) were observed with a much higher frequency
than previously reported in untreated patient populations.19
The lack of standard criteria for the definition of resis-
tance makes it hard to compare results from different stu-
dies. In addition, differences in prevalence of primary
resistance may be related to varying distribution of subtypes,
transmission route, and study design. In our evaluation, the
resistance mutations considered were based on the IAS-USA
guidelines (2007 revision)18 without considering solitary
mutations such as the V118I and T69S. With the inclusion
of these mutations in the analysis, the prevalence of primary
drug resistance becomes 8.6%, which is consistent with HIV
primary resistance rates reported in non-IDU popula-
tions.10,12,20,21 This being said, the results of our study sup-
port the findings of an earlier study that has shown an
extremely low frequency of transmission of drug-resistant
HIV strains among recent IDU seroconverters.22
Notably, there was some level of discordance between our
genotypic and phenotypic results. Two patients who had
resistant genotypes (T215D and L100I) had phenotypes within
the normal susceptible range. The mutation T215D is a
revertant mutation that is phenotypically not interpreted
as resistant, while in the case of L100I, the BCO value was
below the threshold of resistance (CCO values were not
available). On the other hand, two patients who had resistant
phenotypes did not have major genotypic mutations; how-
ever, they were resistant to nelfinavir because they had
multiple minor PI mutations. As reported in the literature,
discordance between genotypic and phenotypic results is
common and is probably due to having different algorithms
and interpretations of test results.23,24
Some authors have suggested that IDUs are more likely
to carry HIV isolates with primary drug resistance.25 Our
results do not support this, with a prevalence below 5%,
corresponding to the lower end of rates reported even in
non-IDU populations. This might seem quite surprising
since non-optimal management and care of IDUs living
with HIV, poor adherence to treatment, relapse to illicit
drug use, and risky drug injecting as well as sexual beha-
viors might lead to higher levels of resistance being trans-
mitted within this population. However, this is probably
mitigated by limited prior exposure of IDUs to antiretro-
viral medications associated with problems of access to
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Primary drug resistance in antiretroviral-naı¨ve injection drug users 581care and less likelihood of prescribing HAART to IDUs
because of the very issues outlined above.26,27
Interestingly, there was no increasing trend in the pre-
valence of resistance mutations by year of enrollment. While
a stable prevalence of primary drug resistance was detected
in some studies,28,29 others showed an increase in prevalence
of resistance.5,11,20,30 The stability of prevalence of HIV
primary drug resistance in IDUs may be related to the adop-
tion of prevention programs, as well as structured treatment
programs such as DOT directed at this population as HAART
was being considered on a more widespread basis.
A limitation of the study is that it was done in patients with
chronic rather than acute infection, thereby possibly under-
estimating the true prevalence of primary resistance. How-
ever, several studies have demonstrated the persistence of
primary resistance mutations for periods of up to five years
following the date of infection (especially for NNRTIs),31—33
supporting the rationale for testing the chronically infected
individuals and relying on such data as a representation of at
least the true risk of transmission of NNRTI primary resis-
tance. Second, some studies have shown that drug-resistant
low level minority species, not detected by standard geno-
typic resistance testing, may be transmitted and yet may
impact the success of antiretroviral therapy.34 This remains a
possibility, but the overall virologic success of HAART
observed in our population does not suggest that this was
a major factor in our study group. Third, when comparing
rates of virologic suppression among patients with and with-
out primary drug resistance, some caution is warranted since
our results are based on very few patients with drug resis-
tance. Fourth, although this study did not include data for the
actual phenotype, several studies have demonstrated an
excellent correlation between interpretations derived from
the virtual and the actual phenotype, suggesting that the
virtual phenotype is a viable alternative for the actual
phenotype.35,36 Fifth, the results of our study represent only
one clinic and may not be completely transferable to other
IDU populations. Finally, in IDU populations, confounding
factors may be substantial. For example, a wild-type virus
cluster spreading rapidly may be heavily over-represented
and may therefore strongly influence prevalence of primary
resistance. In our study, a phylogenetic analysis to assess this
question was not done. However, the long recruitment time
and the diversity of the population argue against this being a
significant issue in our results.
In conclusion, the prevalence of primary drug resistance in
our population of IDUs is relatively low (<5%). The standard of
care in developed countries now mandates the use of resis-
tance testing prior to the prescription of initial HAART regi-
mens.37 However, if one were to need to initiate HAART in one
of our IDUpatients onanurgent basis, ourdata suggest that the
use of a PI-based regimen would probably be most effective.
We will continue to monitor this parameter over time to
establish whether any change in this prevalence is occurring
and whether it should lead to specific guidelines for the
initiation of HAART in this population, especially when indivi-
dual drug resistance test results are not readily available.
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